The UV research groups (GIUV) are regulated in the 1st chapter of the Regulation ACGUV48/2013, which explains the procedure for creating new research structures. They are basic research and organizational structures that result from the voluntary association of researchers that share objectives, facilities, resources and common lines of research. These researchers are also committed to the consolidation and stability of their activity, work in groups and the capability to achieve a sustainable funding.
The research groups included in the previously mentioned Regulation are registered in the Register of Research Structures of the Universitat de València (REIUV), managed by the Office of the Vice-principal for Research and Scientific Policies. The basic information of these organisms can be found in this website.
Participants
Data related to research groups featured in various information dissemination channels shall not, under any circumstances, imply a statement or commitment regarding the employment or academic affiliation of individuals associated with the Universitat de València. Their inclusion is solely the responsibility of the group directors. Updates will be made upon request from interested parties.
- Registered groups in the Register of Research Structures of the Universitat de València - (REIUV)
Reference of the Group:
Description of research activity: Currently, the group's main research activity is focused on the study of high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC).We essentially focused on the study of the generation of drug resistance through cell models, murine models and patient samples.
Web:
Scientific-technical goals: - Study of AXL-GAS6 as a mechanism of resistance to PARP inhibitors in COSAG and CMTN through replicative stress and immunomodulation
- Analysis of the role of the p53-Aurora kinase pathway as potential predictive biomarkers and therapeutic targets in COSAG and CMTN
- Analysis of AXL and the epithelial-mesenchymal transition as a mechanism of resistance to PARP inhibitors in high-grade ovarian cancer
- Study of the role of trabectedin in reversal to resistance to platinum and PARP inhibitors
Research lines: - Study of the generation of drug resistance in high-grade serous ovarian cancer and triple negative breast.The group focuses on studying the generation of mechanisms of resistance to different drugs used in clinical practice for ovarian cancer, specifically high-grade serous ovarian cancer (HGSOC) and triple negative breast cancer (TNBC).
Group members:
CNAE:
Associated structure:
Keywords: - Cancer
- cáncer; mama; ovario; resistencias; fármacos
- PHARMACEUTICALS
